KMT2A and acute myeloid leukemia: Since a consequence of DOT1L inhibition commonly observed in both MLL-r and non-MLL-r AML cell lines was myelomonocytic differentiation, we first analyzed whether the differentiation stage affected the response to Sorafenib treatment.